A Multicenter Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Target patients aged 18-75, including those aged 18 and 75
• Primary IgA nephropathy diagnosed by renal biopsy within 3 months
• eGFR≥30ml/min/1.73m2
• 24-hour urine protein ≥ 1.0g/d, or UPCR ≥ 0.8 g/g
• Sign informed consent
Locations
Other Locations
China
Sichuan Provincial People's Hospital
RECRUITING
Chengdu
Contact Information
Primary
Guisen Li, Doctor
guisenli@163.com
+86-28-87393340
Time Frame
Start Date: 2024-10-30
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 200
Related Therapeutic Areas
Sponsors
Leads: Sichuan Provincial People's Hospital